Pneumonia vaccine & immune booster sales surged

Immune booster products were temporarily out of stock

Prevenar is estimated to have increased sales 9 times compared to last February

COVID-19 outbreak lasted for one month, and sales of pneumococcal vaccines and immune boosters also increased.

 

Prevenar 13

According to the industry on the 20th, Pfizer's pneumococcal vaccine, Prevenar 13, Prevena 13 sales soared during COVID-19 outbreak.

 

According to Chong Kun Dang, which is currently in charge of domestic sales of Prevenar, Prevena 13 sales soared since February, when the COVID-19 crisis began in earnest in Korea.

 

An official from Chong Kun Dang said, "There is no accurate statistics, but the sales volume so far has increased by 50% compared to last month.

 

By the end of this month, it is expected to grow 900% from last year".

 

"Vaccinations are usually the highest in October-December because of the nature of vaccines, and it is currently observed that sales volume is at the level of November-December", he said.

 

In some regions, there are also concerns about out of stock.

 

An official of Pfizer Pharmaceuticals, a manufacturer, said, "We understand that the sales volume has increased, and we’ll our best to supply smoothly".

 

Chong Kun Dang has been in charge of domestic distribution of prevenar for adults since December 2017.

 

Previously, Yuhan Corporation was in charge of distribution.

 

Prevenar is the top seller in the global pneumococcal vaccine market.

 

In Korea, the company records annual sales of ￦30 billion.

 

Prevenar has not been shown to be effective in preventing pneumonia caused by COVID-19.

 

Prevenar, a pneumococcal vaccine, is literally a vaccine against pneumococcal infection.

 

Pneumococci are one of the leading causes of pneumonia, accounting for 27-44% of the causes of pneumonia.

 

The causative organism is different from COVID-19, and in principle it is impossible to prevent it.

 

However, some experts recommend that inoculation of pneumococcal vaccines may help relieve symptoms.

 

Although pneumonia caused by COVID-19 cannot be prevented, it helps to pass through only the mild symptoms of pneumonia.

 

Aronamin products

In addition to Prevenar, sales of immunity-related products also surged.

 

It is a vitamin B·C product.

 

Ildong Pharmaceutical's Aronamin product is a typical example.

 

Ildong Pharmaceutical official said, "As we know, the sales volume of the aronamine product has increased by 40~50% compared to in January".

 

In addition, Daewoong's 'Impactamine' and Chong Kun Dang's 'Benfobel' are reported to have increased in February.

 

It is analyzed that it is influence of COVID-19 outbreak.

 

Although it is not a vitamin product, Echinaforce, a respiratory immune enhancer of Hanwha Pharm, suffered a temporary out of stock situation early in the outbreak.

 

According to Hanwha Pharmaceutical, the supply of this product was resumed on the 20th.

 

An official of Hanwha Pharm said, "COVID-19 is showing signs of spreading, which is unexpected, leading to inquiries about products, and we did our best to supply urgently".

 

Echinaforce is mainly derived from the raw material Echinacea.

 

Hanwha Pharm explained that it could help to boost antiviral, anti-inflammatory and immunity.